前立腺肥大症症例に対するAstromicin投与後の前立腺組織内および血清中濃度について

Abstract

ASTM 200 mg筋注後の前立腺組織内濃度を前立腺肥大症患者にて測定した結果, 3.79±1.01 μg/gの組織内濃度を得た.この濃度は経口投与剤であるenoxacinの前立腺組織内濃度とほぼ匹敵するものと考えられた

The present study was undertaken to evaluate the penetration of astromicin sulfate into prostatic tissue. Twenty eight patients with benign prostatic hypertrophy entered the study. Astromicin sulfate was administered as an intramuscular injection in a dose of 200 mg one hour preoperatively. Blood samples were taken simultaneously with the tissue sampling at the transurethral resection of the prostate. The mean concentration of astromicin sulfate in prostatic tissue was 3.79 +/- 1.01 micrograms/g and that in serum was 10.25 +/- 2.70 micrograms/ml.